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Abbreviations  
Ulcerative Colitis: UC 
Mucosal Healing: MH 
Federal Drug Agency: FDA 
Mayo endoscopic subscore: Mayo  
Ulcerative Colitis Endoscopic Index of Severity: UCEIS  
The ulcerative colitis colonoscopic index of severity : (UCCIS) 
Robarts Histological Index: RHI 
New York Mount Sinai system developed by Harpaz : NYMS 
White Light Endosocpy: WLE 
High definition: HD 
Virtual electronic Chromoendoscopy: VEC 
The Paddington International Virtual Chromoendoscopy score :PICaSSO  
High-definition white light =iSCAN 1 
High-definition electronic virtual Chromoendoscopy =iSCAN 2 and 3 
 
Key words : Ulcerative Colitis , endoscopic scores , iscan, virtual 
Chromoendoscopy , Mucosal Healing  
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Abstract  
Introduction: Endoscopic inflammation and healing are important 
therapeutic endpoints in ulcerative colitis (UC). We developed and validated 
a new electronic virtual chromoendoscopy (EVC) score that could reflect the 
full spectrum of mucosal and vascular changes including mucosal healing in 
UC.  
Methods: Eight participants reviewed a 60-minute training module outlining 
the three different i-SCAN modes demonstrating the entire spectrum of 
inflammatory mucosal and vascular changes in UC. Performance 
characteristics in endoscopic scoring and predicting the histologic 
inflammation with EVC (i-SCAN) by using 20 video clips before (pre-test) 
and after (post-test) were evaluated. Exploratory univariate factor analysis 
was performed on “PICaSSO” score covariates for mucosal and vascular 
score separately. Subsequently a proportional odds logistic regression model 
for the prediction of histological scores were analyzed. 
Results: The interobserver agreement for Mayo endoscopic score in the pre-
test (k=0.85; 95% CI, 0.78-0.90) and the post- test (k=0.85; 95% CI, 0.77-
0.90) evaluation were very good. This was also true for UCEIS in the pre 
and post-test score interobserver agreement (k= 0.86;95% CI, 0.77-0.92 and 
k=0.84; 95% CI, 0.75-0.91). The interobserver agreement of the PICaSSO 
endoscopic score was very good in the pre and post-test evaluations (k= 
0.92; 95% CI, 0.87-96 and k= 0.89; 95% CI, 0.84-0.94). The accuracy of the 
overall PICaSSO score in assessing histological abnormalities and 
inflammation by Harpaz score was 57% (95% CI, 48%-65%), by RHI 72% 
(95% CI, 64%-79%) and by ECAP (full spectrum of histologic changes) 
83% (95% CI,76%-88%). 
 
Conclusion: The EVC score “PICaSSO” showed very good interobserver  
agreement. The new EVC score may be used to define the endoscopic 
findings of the mucosal and vascular healing in UC and reflected the full 
spectrum of histological changes.  
 
Introduction 
Endoscopic assessment of mucosal inflammation and mucosal healing (MH) 
is a critically important component of determining the severity of ulcerative 
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colitis (UC) in clinical trials and in clinical practice (1,2). The Federal Drug 
Agency (FDA) is stipulating the use of endoscopic score combined with 
patient reported outcomes (PRO2 – rectal bleeding, bowel frequency) in 
evaluating the efficacy and outcome in the treatment of UC by novel 
emerging therapeutic agents. (3)  
 
The Mayo endoscopic subscore is the most widely used endoscopic scoring 
system. Although never formally validated, the Mayo endoscopic score is 
simple and has operating characteristics that are easily applicable for scoring 
the degree of mucosal inflammation in UC by individual gastroenterologists 
and trained central readers reporting from video recordings (4-7). Mayo 
endoscopic score may vary from 0 to 3 and at each scoring level several 
features must be considered. Mayo score does not consider vascular changes 
but with the new generation of high-definition (HD) colonoscopes with or 
without electronic virtual chromoendoscopy (EVC), vascular patterns are 
often appreciated as abnormal, but not absent. Friability is another feature in 
the Mayo score that is open to subjective interpretation.  Despite there are 
important endoscopic difference between Mayo score 0 and 1, both of these 
are considered mucosal healing in clinical trial and in clinical practice, but 
histological changes may still be present.  It is also clear that there are 
clinically meaningful outcome differences between Mayo endoscopic 
subscore of 0 and 1.  Although studies have established that mucosal healing 
(Mayo endoscopic score of 0 or 1) have reduced risk of flares or colectomy, 
it is important to note that recently Barrreiro –de Acosta et al (8) have shown 
that the risk of recurrence in UC patients with Mayo endoscopic score of 1 is 
higher (36.6%) compared with Mayo score 0 (9.4%) . 
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In order to overcome some of the limitations of Mayo endoscopic subscore, 
more detailed scoring systems have been recently developed and validated. 
It is not clear whether these new scores, Ulcerative Colitis Endoscopic Index 
of Severity (UCEIS) and the Ulcerative Colitis Colonoscopic Index of 
Severity (UCCIS) are superior in their operating characteristics to Mayo 
endoscopic subscore. (9-11, 30)  
 
In addition, no validated scoring systems for electronic virtual 
chromoendoscopy is available. These techniques are currently available on 
all endoscopic platforms and provide better mucosal and vascular details 
than conventional WL endoscopy. Iacucci et al (12) have recently described 
an endoscopic scoring system using i-SCAN electronic virtual 
chromoendoscopy to assess inflammation in UC. They have shown that  
measure of abnormal vascular pattern may correlate with histologic indices.  
 
In this study, we aimed to develop a new electronic virtual 
chromoendoscopy score (EVC), which was more comprehensive in 
including details of subtle vascular and mucosal changes reflecting chronic 
and acute inflammation in UC patients using HD equipment with EVC. We 
wanted to better define the characteristics of endoscopic MH in UC patients  
and therefore we  considered and included all the subtle  chronic and acute 
inflammatory changes of vascular and mucosal pattern. We aimed to 
validate for the first time a new PICaSSO-Score (The Paddington 
International virtual ChromoendoScopy ScOre), by determining the 
intraobserver and interobserver agreement among international experts, to 
assess the correlation with standard endoscopic UC scores and the 
correlation to several histological scores.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 8 
 
Study Design & Methods 
 
Ethical approval  
The study was approved by the Conjoint Health Research Ethics Board 
(CHREB) of the University of Calgary, Alberta, Canada.  
All authors had access to the study data and reviewed and approved the final 
manuscript. 
 
Participants 
A total of 8 gastroenterologists and 2 pathologists experienced in IBD and 
advanced endoscopic imaging techniques participated in the London 
consensus. The gastroenterologists had performed an average of 8000 
colonoscopies in their lifetime and all of them were experienced in the i-
SCAN virtual chromoendoscopy technology (Pentax, Japan) and 7 with NBI 
(Olympus, Japan). All of them were also familiar and experienced with 
endoscopic scoring systems currently in use in UC such as Mayo endoscopy 
subscore and Ulcerative Colitis Endoscopic Index of Severity Index 
(UCEIS) (4,9-11). 
 
Training module (algorithm) 
A 60-minutes Powerpoint training module was developed and presented at 
the consensus conference held at London. (MI, SG, MD).  
The content of the module included an introduction to the study, an 
explanation of the existing endoscopic scores in use such as Mayo 
endoscopic subscore and UCEIS, the i-SCAN  score developed by Iacucci et 
al.  (4, 9-12), and the role of the histological score to assess inflammation 
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and mucosal healing in UC (SXG, VV). 
The training module consisted of 70 endoscopic pictures and 5 videos and 
were assessed by all the participants with direct feedback and stepwise 
discussion. These illustrated the entire spectrum of inflammatory mucosal 
and vascular changes including mucosal healing in UC. Representative 
slides in Powerpoint from the training module and a video are shown (Figs 1 
-2 and video supplement) 
Video Library 
Twenty high-quality video clips representing collections of different grades 
of inflammation were selected from an existing library. This anonymized 
library was collected by one investigator (M.I.) from surveillance 
colonoscopies or for assessing activity of the disease in UC patients. 
 
 The video clips had a duration of 90 to 120 seconds, showing the degree of 
inflammation by  white light, followed by i-SCAN (EPKi 7000 Pentax EC-
3490Fi in the 3 settings, High-definition white light i-SCAN 1, and 
electronic virtual chromoendoscopy i-SCAN 2 and 3).  Two specimens of 
biopsies were taken in the rectum and in the sigmoid colon and were sent to 
a single expert pathologist (SXG), who was blinded to the endoscopic 
results. The  histological examination were assessed according to the  
existing histological score – NYMS (New York Mount Sinai system) 
developed by Harpaz, (13) the newly validated Robarts Histological index 
(RHI) score (14) and the  newly described Calgary (ECAP) score (12) which 
is more comphrensive in including the acute and chronic changes of 
inflammation in the colonic mucosa in UC. The videos were saved in audio 
video interleave (AVI) format. Of the twenty videos, 5 were severe UC, 5 
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moderate UC, 5 mild  UC, and 5 were quiescient UC, as defined by Mayo 
endoscopy subscores.  
 
Endoscopic form and data collection 
Data was collected from each participant including years in practice after 
training, number of annual colonoscopies and in their lifetime, experience 
with NBI and i-SCAN techniques.   
A structured Case Video Report Form (CVRF) was created for the 
participants to assess the different endoscopic scores (see 
supplement/appendix).  
 
Development of the new virtual chromoendoscopy score in UC  
(PiCaSSO score) 
The study was conducted in 4 phases: Phase 1, training module with pictures 
of the previous i-SCAN  score developed by Iacucci et al and development 
of EVC classification system for endoscopic assessment of mucosal and 
vascular healing in UC after  feedback and stepwise discussion between the 
experienced gastroenterologists ; phase 2  powerpoint training module of  
seventy i-scan pictures and 5 videos ; phase 3 (pre-test), evaluation of 
intraobserver and interobserver agreement between gastroenterologists 
experienced in EVC and IBD in scoring different endoscopic systems in UC 
(Mayo endoscopic subscore, UCEIS, i-SCAN virtual chromoendoscopy and 
the new PICaSSO score using video clips in the pre-test fashion for  
different  grades of inflammation ; phase 4 (post-test), validation of the  
endoscopic findings criteria and the overall classification  using the same 
videos in a post–test fashion after a second training module. 
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The videos included and considered in the teaching module were not 
included in the validation pre-test and post-test scores between the raters. All 
endoscopist raters were blinded to clinical history, clinical activity and 
number of videos in each category. 
First and second phases  (First day of the London consensus) 
The new PICaSSO virtual chromoendoscopy score was developed by the 
consensus group in a stepwise fashion using videos and still pictures. We 
based our assessment on the framework of our endoscopic experience in 
virtual digital and optical chromoendoscopy, previous i-SCAN and NBI 
score which recently has been assessed and modified for mucosal 
inflammation that specifically characterizes vascular and mucosal changes 
which correlate well with histological scoring systems and clinical outcomes 
Table 1. (15-20). 
 
Third phase (Pre-test) 
All participants were provided with the pre-test videos and instructed to 
enter their responses in the CVRF. A total of 20 high-definition video clips  
was shown to the participants and on completion of the forms, these were 
handed over to the coordinator of the consensus. The endoscopists rated all 
the videos as high quality as part of their evaluation. The participants did not 
exclude any video because of concern about quality. All videos were from 
routine clinical practice. 
 
Fourth phase (Post-test) 
 An additional teaching module of 10 videos of different grade of UC 
inflammation and with direct feedback and discussion, was presented on the 
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second day of the consensus. After that, the same 20 videos clips, in a 
different order, was provided to the participants – the period between pre-
test and post test minimized recall bias.  
 
Histologic assessment 
An IBD histological grading scheme NYMS (New York Mount Sinai 
System) developed by Harpaz (13), and the Robarts Histological Index 
(RHI) were used for comparison (14) with endoscopic scores. A 
comprehensive and more detailed histological characterization, which 
reflected all the chronic and acute changes of inflammation, were 
independently performed by a single gastrointestinal histopathologist (SXG) 
who was blinded to the endoscopic findings. This scoring (ECAP system – 
Extent, Chronicity, Activity, Plus additional findings) system was 
previously designed independently by SXG alongside the i-SCAN score to 
assess all, including even minimal chronic mucosal changes in UC (12). This 
grading/scoring, including (1) Extent of mucosal inflammation (E), (2) 
Chronicity  (C), ie, changes indicative of a chronic inflammatory process, 
(3) Activity (A), ie, the degree of active (neutrophilic) inflammation, and (4) 
plus other additional findings (P), including eosinophilia and lymphoid 
follicles/aggregates, both being relatively nonspecific to any particular 
process. The details of the scoring system are shown in Supplementary 
Tables 1, 2, and 3, available online.   
 
Statistical Analysis 
Software 
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All the responses of the raters were transferred to a Microsoft Excel 
(Microsoft Inc, Redmond, Wash) database and exported to for statistical 
analysis.  
Statistical Analysis was performed using the R system for statistical 
computing version 3.2.2 (R Core Team, 2015) 
 
Analysis of Rater Agreement 
Intraobserver and interobserver agreement was assessed for pre and post 
training time points for Mayo, UCEIS, i-SCAN Mucosal, i-SCAN Vascular, 
i-SCAN Total, Picasso Mucosal, Picasso Vascular and Picasso Total scores 
using Cohen's Kappa for Multiple Raters.  Confidence intervals for each 
Kappa estimate were calculated using the adjusted bootstrap confidence 
interval procedure described in DiCiccio and Efron (1996) (21). Tests for 
equality of Kappa estimates pre and post training were performed using a 
non-parametric bootstrap p-value estimated using 1000 samples.  
We obtained the sample size by considering the ability to detect 0.15 to 0.20 
points of Kappa statistics difference with 2 tailed test at 80% power; fifteen 
to19 videos were sufficient for this purpose.  In this study, a sample size of 
160 observations (20 videos, 8 reviewers) was calculated to be adequate to 
detect this difference with 80% power and an alpha of 0.05.  
 
Model Coefficient Selection 
 Exploratory univariate factor analysis was performed on Picasso co-variates 
for Mucosal, Vascular and Overall Score separately. Subsequently a 
proportional Odds Logistic Regression Models for the prediction of 
Histological Score (1-4), and Linear Regression Models of ECAP (1-26) and 
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RHI (1-33) scores were fit using co-variates indicated from the exploratory 
factor analyses. 
  
Model Assessment   
Model based predictions of histological Scores Harpaz, ECAP and RHI were 
assessed for prediction accuracy and correlation between predicted and true 
scores using a bootstrap sample based cross validation procedure.  Accuracy 
and Kendal (Harpaz Score) or Pearson (ECAP or RHI Score) correlations 
are presented as measures of model quality.  Accuracy was defined as 1-
Misclassification Rate. Misclassification in the Histological Score was 
defined as any predicted value that did not equal the true histological 
score.  In ECAP and RHI scores misclassification was defined as any model 
based prediction that fell outside of + 1 minimum clinical important 
difference unit for each scale.  ECAP and RHI minimal clinically important 
difference values were 4 and 6 units, respectively.  
  
Results 
Interobserver agreement between the endoscopic scores  
The overall interobserver agreement for Mayo endoscopic subscore between 
the endoscopists in the pre-test (k=0.85; 95% CI, 0.78-0.90)  and the post 
test (k=0.85;  95% CI, 0.77-0.90) evaluations was very good, as well as for 
UCEIS in the pre- and post test score (k= 0.86; 95% CI, 0.77-0.92 and 
k=0.84; 95% CI, 0.75-0.91). The overall interobserver agreement for i-
SCAN score to assess inflammation was at baseline (k= 0.75; 95% CI, 0.66-
0.83), and after training k= 0.76 (95% CI, 0.65-0.84). The interobserver 
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agreement of the new PICaSSO overall endoscopic score was considered 
very good in the pre- and post test evaluation (k= 0.91; 95% CI, 0.87-096 
and k= 0.89; 95% CI, 0.84-0.94) Figure 3. 
Intraobserver agreements of Mayo endoscopic subscore, UCEIS, i-SCAN 
mucosal, vascular and overall score, PICaSSO score are shown in Table 2. 
Sensitivity analyses were carried out, and excluding most severe cases 
(Mayo 3), more remitting cases (Mayo 0) and selectively removing any 
subgroup of reads based on Mayo scoring classification, did not lead to any 
meaningful difference in interobserver agreement measured by means of 
kappa statistics. 
 
Correlation between the existing endoscopic, histological scores and the 
new PICaSSO score 
The correlation between Mayo, UCEIS, i-SCAN mucosal, vascular, overall 
and PICaSSO mucosal, vascular and overall with Harpaz, RHI and ECAP 
histological scores are showed in Supplementary Table 4, online. The new 
PICaSSO score correlated also well with all the histological scores but better 
with the ECAP than RHI score that includes acute but also chronic and 
subtle inflammatory changes of the colonic mucosa. 
Multivariate logistic regression analysis and accuracy of the PICaSSO 
score  
Exploratory statistical model analysis was performed and showed that the  
endoscopic mucosal  features of continuous/regular crypts, crypts not visible 
(scar), discontinuous and or dilated/elongated crypts and vascular  pattern 
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findings such as roundish after crypt architecture, vessels not visible (scar), 
sparse (deep) vessels without dilatation were associated with  healing in UC  
whereas  micro-erosions and  crowded dilated vessels  were  associated  with 
mild inflammation . Subsequently a proportional Odds Logistic Regression 
Models for the prediction of Histological Score (1-4), and Linear Regression 
Models of ECAP (1-26) and RHI (1-33) scores were performed for the final 
development of PICaSSO score and confirmed that these endoscopic 
features were predictors of mucosal healing and activity of the disease. 
Table 3. 
The accuracy of the new PICaSSO score to predict mucosal healing and 
inflammation by using the 3 histological score (Harpaz, RHI and ECAP) 
was determined and is showed in Figure 4. 
 
The PICaSSO mucosal, vascular and overall score predict better histological 
healing and inflammation abnormalities when it was used with the ECAP 
and RHI histological scores then compared with Harpaz score. The accuracy 
of the overall PICaSSO to assess histological abnormalities and 
inflammation by Harpaz score was 0.57% (95% CI, 0.48-065) by RHI 
0.72% (95% CI, 0.64-079) and by ECAP 0.83% (95% CI, 0.76%-0.88) 
(Figure 4). 
 
Discussion  
To our knowledge, this is the first validated endoscopic score using the new 
generation of virtual chromoendoscopy endoscopes in UC. The PICaSSO 
score performed better than the previously published i-SCAN score by 
Iacucci et al. (12).  
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The newly developed PICaSSO score defined for the first time the 
endoscopic findings of the mucosal and vascular healing in UC using EVC 
and reflects the whole range of the endoscopic spectrum of inflammation.  A 
precise endoscopic assessment of subtle inflammation may be further 
explored in future in terms of relationship to clinical outcomes.  
(22-24) 
 
However, the endoscopic evaluation of MH in UC still remains an important 
challenge. Multiple endoscopic scores, partially validated, have been 
developed using the previous generation of WLE and have several 
limitations in the assessment of inflammation in UC accurately. In addition, 
the distribution of inflammation can be subtle, patchy and easily missed by 
WLE and random biopsies (15, 25-28). 
 
On the other hand, the Mayo endoscopic subscore is widely used in clinical 
practice and in clinical trials, as it is easy to use by experienced 
gastroenterologists and has been found to have adequate interobserver and 
intraobserver agreement   but is limited in the ability to be reproduced by 
less experienced gastroenterologists. In addition it is not ideal in detecting 
subtle inflammation at the lower end of the range and to differentiate well 
between mucosal healing and mild inflammation, as the range is a limited 0-
3 score (4,30).  
 
Recently, it has also been shown that patients with a Mayo endoscopic score 
of 1, which is considered in clinical trials as mucosal healing, have a high 
rate of recurrence compared with a score of 0 (8). In our article we have 
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confirmed a reproducibility and a good correlation between the Mayo 
subscore and all histological scores. The aim of the PICaSSO score was to 
distinguish between Mayo subscores 0 and 1 because Mayo 1 does not truly 
represent mucosal healing.  
 
Iacucci et al have recently developed EVC score for UC that defines subtle 
inflammation and mucosal healing. They have also designed a new 
histologic grading/scoring system (ECAP system – Extent, Chronicity, 
Activity, Plus additional findings) to be fully reflective of every chronic or 
acute inflammatory histological changes in UC (12). These have shown a 
high degree of correlation between the   i-SCAN scores and the Mayo 
subscore and Harpaz histological grading. However, complete MH defined 
by endoscopic Mayo subscore 0 still demonstrated abnormalities by using 
EVC and the histological ECAP score.  
 
The London consensus developed and validated a more detailed endoscopic 
score, using the latest generation of high-definition virtual electronic 
chromoendoscopy endoscopes that could better define and characterize 
endoscopic mucosal healing and all the spectrum of mild and more severe 
inflammatory changes in UC patients. The new PICaSSO score embraced all 
the endoscopic findings of the inflammation in UC and performs better than 
the previous i-SCAN score developed by Iacucci et al. (12). 
 
Previous studies have shown a large variance of intraobserver and 
interobserver agreement between gastroenterologists to assess the 
endoscopic activity in UC (5,29). The panelists of the London consensus had 
a very good intraobserver and interobserver variability in scoring endoscopic 
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inflammation in UC using all the endoscopic scores including the new 
PICaSSO score.  
 
Our data suggest that the consistent evaluation of endoscopic inflammation 
between observers can most likely be attributed to the computer based 
training module, the stepwise feedback and the experience in advanced 
imaging techniques of the observers. 
 
The PICaSSO score if further validated in multicenter studies, may turn out 
to be a reliable instrument for measuring endoscopic inflammation as 
mucosal and vascular changes in UC patients. 
The endoscopic findings of mucosal and vascular healing such as 
continuous/regular crypts, crypts not visible (scar), discontinuous and or 
dilated/elongated crypts and vascular pattern findings such as roundish after 
crypt architecture, vessels not visible (scar), sparse (deep) vessels without 
dilatation predicted histological remission versus  mild inflammation  
especially when these were used with the  new more precise histological 
scores RHI and ECAP .(13-14) 
 
Adding support to these results Hayashi et al have recently demonstrated 
that magnifying NBI observation of mucosa was effective for the assessment 
of UC follow-up.  The endoscopic vascular pattern features were accurately 
assessed by NBI with magnification and were important predictors of UC 
relapse (20). Hayashi et al reported the vascular findings alone without the 
mucosal findings in the abstract. The vascular findings with NBI are similar 
to i-SCAN and it is likely that a common EVC score may be developed 
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irrespective of the exact EVC platform; ongoing studies will address this 
important issue. 
 
We have introduced for the first time an integrated EVC score for mucosal 
and vascular patterns to better assess and grade inflammation and MH in 
UC. However, the experienced raters performed better in assessing mucosal 
pattern compared with the vascular pattern.  This might be explained by the 
fact that the detailed electronic vascular endoscopic score is a new 
development concept, also for experienced observers. We are planning to do 
learning curve assessment in future using extended teaching phase divided 
into quartiles using endoscopists with varying levels of experience ; 
however, in this phase of development of the PICaSSO the participants were 
experts in i-SCAN and optical diagnosis technology and so we did not 
directly address the learning curve.  
 
 In the long term, the PICaSSO score needs to be validated in a multicenter 
prospective study. Multicenter real life studies are ongoing to validate the 
PICaSSO scores across different international centers under a variety of 
conditions. In this study, although the sample size in terms of videos read by 
the observers (n=20) might seem to be low, the sample size estimate 
mentioned above was accomplished. Moreover in some recently published 
papers the dataset of videos analysed did not exceed this number (5 to 11 
videos) or the dataset was slightly larger, but readers concentrated on a 
smaller subset of videos  (39 videos); (16 videos/reader). (31-33) A 
generalization to more than 2 categories was needed in order to obtain our 
results about multilevel non-dichotomous ratings. Asymptotic distributions 
of kappa statistics and their differences with many raters, many rating 
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categories and two conditions. (34). The raters did see the white light images 
and scored Mayo and UCEIS which may be considered a limitation in terms 
of scoring in the i-SCAN mode but this is also the real life situation. 
Furthermore, it would be relevant to evaluate the reproducibility of the 
PICaSSO score in community centers and gastroenterologists with less 
experience in this technique. This would also allow assessing the educational 
training tool used in this study to assess the learning curve in new observers. 
More work is needed to converge to one simple and accurate EVC score that 
could be applied to all available and future endoscopic platforms. Indeed, 
adequate assessment of endoscopic healing may help in patient management 
and the outcome of the disease in our patients.  
In conclusion, we have developed and validated new EVC score for UC 
incorporating more detailed mucosal and vascular findings on I-SCAN that 
holds the potential to better correlate with mucosal healing. 
Figures  
 
Figure 1: Endoscopic mucosal healing :a-d) High-definition i-SCAN 1and 
virtual chromoendoscopy i-SCAN 2  showed elongated crypts  
 
 
Figure 2. Endoscopic vascular healing a-d ) High-definition i-SCAN 1and 
virtual electronic chromoendoscopy i-SCAN 2 -3 showed sparse ( deep) 
vessels without dilatation.   
 
 
Figure 3. Interobserver variability between the endoscopic scores  
 
Figure 4. Accuracy of the PICaSSO score to assess  mucosal healing and 
inflammation in UC 
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 Table 1 : The Paddington international virtual chromoendoscopy score 
(PICaSSO )in UC 
PICaSSO MUCOSAL ARCHITECTURAL 
 
• 0 - No mucosal defect 
– A: Continuous/regular crypts 
– B: Crypts not visible (scar) 
– C: Discontinuous and or dilated/elongated crypts 
• I - Micro erosion or cryptal abscess  
• 1 : discrete 
• 2: patchy   
• 3: diffuse 
• II- Erosions size <5 mm 
• 1:discrete 
• 2:patchy  
• 3: diffuse 
• III -Ulcerations size >5 mm 
• 1:discrete 
• 2:patchy  
• 3: diffuse 
•  
PICASSO VASCULAR ARCHITECTURE  
 
• Vessels without dilatation 
– A :Roundish following crypt architecture 
– B: Vessels not visible (scar) 
– C:Sparse (deep) vessels without dilatation 
• I  Vessels  with dilatation  
– A roundish with dilatation 
– B crowded or tortuous superficial vessels with dilatation 
• II Intramucosal bleeding  
– A roundish with dilatation 
– B crowded or tortuous superficial vessels with dilatation 
• III - Luminal bleeding  
• A roundish with dilatation 
• B crowded or tortuous superficial vessels with dilatation 
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Table 2 : Intra-observer variability between endoscopic scores  
Endoscopic score  K pre-test K post-test 
Mayo  
(95% CI) 
0.85 
(0.786-0.909) 
0.85 
(0.781-0.913) 
UCEIS 
(95% CI) 
0.868 
(0.783-0.925) 
0.840 
(0.749-0.917) 
i-scan mucosal 
(95%CI) 
0.732 
(0.623-0.824) 
0.713 
(0.63.5-0.788) 
i-scan vascular 
(95%CI) 
0.632 
(0.511 - 0.760) 
0.664 
(0.501- 0.795) 
i-scan overall 
(95%CI) 
0.757 
(0.666- 0.845) 
0.760 
(0.647- 0.839) 
PICaSSO mucosal  
(95% CI) 
0.911 
(0.849- 0.954) 
0.90 
(0.835- 0.947) 
PICaSSO vascular  
(95%CI) 
0.795 
(0.675-  0.889) 
0.640 
(0.518- 0.809) 
PICaSSO overall 
(95%CI) 
0.917 
(0.878- 0.962) 
0.892 
(0.848- 0.940) 
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Table 3:  Regression Model  of PICaSSo endoscopic findings  for the prediction of the 
Histological scores ( Harpaz, RHI and ECAP) 
 
Harpaz score ECAP score RHI score 
PICaSSO  Mucosal Findings  Coeff. Lower 
bound 
Upper 
bound 
P 
value 
Coeff Lower 
bound 
Upper 
bound 
P 
value 
Coeff Lower 
bound 
Upper 
bound 
P 
value 
 
Continuous/regular crypts -2.664 -3.47047 -1.8579 0 -8.643 -11.0686 -6.21751 0 -12.577 -16.3698 -8.783865 0 
 
Crypts not visible (scar) 
-7.229 -11.82646 -2.6324 0.002 -7.229 -11.8264 -2.63241 0.0020 -10.548 
 
-17.658 
 
-3.43773 
 
 
0.0036 
Discontinuous 
dilated/elongated crypts 
 
-1.88 
 
-2.655034 
 
-1.1044 
 
2.00E 
 
-7.818 
 
-10.66395 
 
-4.97226 
 
0 
 
-12.154 
 
-16.539 
 
-7.7677 
 
0 
Micro erosion or cryptal 
abscess 
 
1. Discrete  
 
-0.904 
 
 
 
-1.88154 
 
0.07381 
 
0.069 
 
-5.714 
 
-9.9923 
 
-1.4350 
 
0.088 
 
-9.704 
 
-16.280 
 
-3.1266 
 
0.03 
2.Patchy 0.521 -0.6347 1.677 0.376 2.969 -2.4906 8.428 0.2865 7.396 -0.9884 15.78 0.083 
3. Diffuse 2.888 2.04 3.737 0 8.899 6.248 11.55 0 12.805 8.657 16.953 0 
Erosions  
size <5 mm 
 
1. Discrete  
 
-0.767 
 
 
-1.793324 
 
 
0.25933 
 
 
0.142 
 
-4.632 
 
 
-9.293621 
 
 
0.02955 
 
 
0.0514 
 
 
-6.412 
 
 
-13.617 
 
 
0.79395 
 
 
0.081 
 
2. Patchy  1.085 
 
0.05559 
 
2.1153 
 
0.038 
 
6.579 
 
1.74227 
 
11.415 
 
0.0076 
 
9 
 
1.509023 
 
16.4909 
 
0.0185 
 
3. Diffuse 2.913 1.980457 3.84499 0 11.751 9.072063 14.4303 0 17.596 13.4175 21.774 0 
 
Ulcerations size >5 mm 
1. Discrete  
 
0 
 
 
-1.79847 
 
 
1.7984 
 
 
0.999 
 
 
-2.69 
 
 
-11.5088 
 
 
6.128 
 
 
0.549 
 
-1.844 
 
 
-15.460 
 
 
11.7714 
 
 
0.7906 
 
2.Patchy 
0.408 -0.52388 1.3402 0.390 3.475 -1.01645 7.9668 0.1294 5.514 -1.41354 12.4419 0.1187 
3. Diffuse             
PiCaSSO Vascular Findings             
Roundish following crypt 
architecture -2.651 -3.784331 -1.5186 4.00E -8.667 -12.0330 -5.3003 0 -11.5 -16.7801 -6.21988 2.00E 
Vessels not visible (scar) 
-3.958 -6.033903 -1.8822 0.00 -8.703 -12.5914 -4.81392 1.20E- -10.901 -16.999 -4.8024 0.0004 
Sparse (deep) vessels  -3.958 -6.033903 -1.8822 0.00 -8.703 -12.5914 -4.81392 1.20E- -10.901 -16.999 -4.8024 0.0004 
IA Vessels  with   roundish 
with dilatation -1.723 -2.49248 -0.9534 1.10E -7.078 -9.916723 -4.24013 1.00E- -10.255 -14.665 -5.8446 5.00E-0 
 IB Vessels with crowded or 
tortuous superficial vessels 
with dilatation 0.51 -0.12829 1.1473 0.11 4 1.376304 6.62369 0.0028 5.813 1.75416 9.8708 0.0049 
IIA Intramucosal bleeding  
roundish with dilatation -0.284 -0.99719 0.4283 0.434 -2.526 -5.75066 0.69923 0.124 -3.829 -8.8053 1.148168 0.1316 
IIB Intramucosal bleeding 
crowded /tortuous 
superficial vessels with 
dilatation 1.371 0.748326 1.99416 1.60E 6.468 4.0831738 8.853020 0 9.15 5.42896 12.8714 1.00E-0 
IIIA Luminal bleeding  
roundish with dilatation 1.772 -0.674129 4.21733 0.155 3.739 -5.071677 12.5505 0.4055 3.57 -10.0388 17.17932 0.6071 
IIIB Luminal bleeding   
crowded /tortuous 
superficial vessels with 
dilatation 18.125 -1336.41 1372.6 0.979 8.171 5.133570 11.20928 0 11.12 6.36046 15.8795 5.00E-0 
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Abbreviations  
Ulcerative Colitis: UC 
Mucosal Healing: MH 
Federal Drug Agency: FDA 
Mayo endoscopic subscore: Mayo   
Ulcerative Colitis Endoscopic Index of Severity: UCEIS  
 The ulcerative colitis colonoscopic index of severity : (UCCIS) 
Rorbart histological index: RHI 
New York Mount Sinai system developed by Harpaz : NYMS 
White Light Endosocpy: WLE 
High definition: HD 
Virtual electronic Chromoendoscopy: VEC 
The Paddington International Virtual Chromoendoscopy score :PICaSSO  
 High definition-white light =iSCAN 1 
High definition electronic virtual Chromoendoscopy =iSCAN 2 and 3 
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Table 1 supplement : Histological  scores  
 
Table 1. IBD Histological Grading Proposal (ECAP System) 
 
Histopatology  Grade/score 
Extent of inflammation (E)  
            Focal 1   
            Multifocal (patchy) 2 
            Diffuse 3 
Chronicity (C)  
C1.Crypt Architectural Alteration   
            None  0 
            Focal Alteration  1 
            Patchy Distortion (<50%) 2 
            Diffuse Distortion (>50%) 3 
C2.Paneth Cell Metaplasia   
            None  0 
            Present  1 
Activity of Inflammation (A)  
A1.Surface Epithelium   
            Normal 0 
            Reactive changes (mucin 
depletion/villiform) 
1 
            Neutrophilic  infiltration / probable 
erosion 
2 
            Erosion  3 
            Ulceration 4 
A2.Neutrophilic Cryptitis  
            None 0 
            >5% 1 
            <50% 2 
            >50% 3 
A3.Crypts Abscess  
           None  0 
           Present  1 
A4.Crypts  Destruction  
           None  0 
           Crypt Destruction 1 
A5.Lamina Propria Mononuclear    
      Cellularity 
 
           Normal 0 
           Mild increase 1 
           Moderate increase 2 
           Severe increase 3 
A6.Basal Plasmacytosis   
           None  0 
           Focal  1 
           Diffuse 2 
A7.Lamina Propria Neutrophilic  
      Infiltration 
 
           None 0 
           Rare 1 
           Scattered 2 
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           Extensive 3 
Plus/Others(P)  
P1.Lamina Propria  Eosinophilic  
      Infiltration 
 
           None 0 
           Mild 1 
           Moderate 2 
           Severe 3 
P2.Lymphoid Follicle /Aggregates   
           None 0 
           Rare 1 
           Prominent 2 
Total Score  
 
 
 
Table 2. Robarts Histologic index score   
 
  
Component 
 
Chronic inflammatory infiltrate  
0=No increase  
1=Mild but unequivocal increase 
2=Moderate increase 
3=Marked increase 
 
Lamina Propria neutrophilis  
0=No increase  
1=Mild but unequivocal increase 
2=Moderate increase 
3=Marked increase 
 
Neutrophils in epithelium  
0=None 
1=<5% crypts involved  
2=<50% crypts involved  
3=>50% crypts involved 
 
Erosion or ulcerations  
0=No erosions ,ulcerations or granulation tissue  
1=Recovering epithelium+adjacent inflamamtion 
1=probable erosion-focally stripped 
2=unequivocal erosion 
3=ulcer or granulation tissue 
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Table 3. New York Mount Sinai scoring system 
                   Score Description 
           0 – inactive colitis 
 
No cryptitis 
           1 – mildly active colitis 
 
Cryptitis in <50% of crypts 
          2- moderately active colitis 
 
Cryptitis in >50% of crypts 
         3 – severely active colitis Ulceration or erosion 
 
 
 
 
Table4 supplement : Correlation(Kendall method) between endoscopic scores and 
histological scores 
 Harpaz ECAP RHI P value 
Mayo  
95%CI 
0.79 
(0.74-0.84) 
0.69 
(0.61-0.75) 
0.62 
(0.52-0.69) 
P<0.001 
UCEIS 
95%CI 
0.74 
(0..67-0.79) 
0.59 
(0.49-0.67) 
0.54 
(0.44-0.64) 
P<0.001 
ISCAN  
Overall 
95%CI 
0.58 
(0.48-0.66) 
0.50 
(0.39-0.60) 
0.44 
(0.32-054) 
P<0.001 
PICaSSO  
95%CI 
0.75 
(0.69-0.81) 
0.64 
(0.55-0.72) 
0.53 
(0.42-0.62) 
P<0.001 
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Appendix 1 
CASE VIDEO REPORT FORM (CVRF) 
 
Name (initials) …………………………..  date ………………………… 
 
Number of years in practice after completion of training 
……………. 
 
Number of colonoscopies performed (approximate)              
Lifetime ………………………Average Per Year…………… 
 
Experienced in NBI:  YES/ NO  
 
Experienced in iSCAN: YES/ NO  
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VIDEO  NUMBER …………………. 
 
High quality  ☐ Low quality ☐   (Choose one) 
 
 
 
MAYO Endoscopic Score  Classification : Mayo 0, Mayo 1, Mayo 
2, Mayo 3 (Choose one from below)  
 
 
 
0 = Normal or inactive disease   
 
1 = Mild disease (erythema, decreased vascular pattern, 
mild friability  
 
2 = Moderate disease (marked erythema, absent vascular 
pattern, friability, erosions)       
 
3 = Severe disease (spontaneous bleeding, ulceration)  
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UCEIS score  (Choose one from each category) 
 
 
 
 
 1.Vascular pattern   A.Normal (0)    ☐ 
     B.Patchy Obliteration (1)  ☐ 
     C.Obliterated (2)   ☐ 
 
 
 2.Bleeding    A.None (0)        ☐ 
     B.Mucosal (1)       ☐ 
     C.Luminal mild (2)       ☐ 
     DLuminal moderate/ severe (3) ☐ 
 
 
3.Erosions and ulcers  A.None (0)    ☐ 
     B.Erosions (1)   ☐ 
     C.Superficial ulcer (2) ☐ 
     D.Deep ulcer (3)   ☐ 
 
 
Total score = 
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iSCAN –UC score  pictures           iSCAN-UC score videos 
 
High quality  ☐ Low quality ☐      High quality  ☐ Low quality ☐    
 
Mucosal pattern: 
1 = normal 
2 = mosaic pattern- Mild  
3 = tubular-gyrus-erosions 
Moderate 
4= nodular rosette- ulcers 
Severe 
Vascular pattern: 
1 = normal 
2 = spiral isolated vessels-Mild 
3 = crowded tortuous vessels-
erythema- Moderate 
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Mucosal pattern: 
1 = normal 
2 = mosaic pattern- Mild  
3 = tubular-gyrus-erosions 
Moderate 
4= nodular rosette- ulcers 
Severe 
Vascular pattern: 
1 = normal 
2 = spiral isolated vessels-Mild 
3 = crowded tortuous vessels-
erythema Moderate 
4= irregular vessels- friability 
Severe  
 
 
Which was the best in your opinion?  Which was the best in your opinion? 
 
HD ☐iSCAN 1 ☐ iSCAN 2 ☐ iSCAN 3 ☐     HD ☐iSCAN 1 ☐ iSCAN 2 ☐ iSCAN 3 ☐     
    Choose one        Choose one  
 
 
 
 
 
 
The Paddington international virtual chromoendoscopy 
score (PICaSSO )in UC 
PICaSSO MUCOSAL ARCHITECTURAL 
• 0 - No mucosal defect 
4= irregular vessels- friability 
Severe  
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– A: Continuous/regular crypts 
– B: Crypts not visible (scar) 
– C: Discontinuous and or dilated/elongated crypts 
• I - Micro erosion or cryptal abscess  
• 1 : discrete 
• 2: patchy   
• 3: diffuse 
• II- Erosions size <5 mm 
• 1:discrete 
• 2:patchy  
• 3: diffuse 
• III -Ulcerations size >5 mm 
• 1:discrete 
• 2:patchy  
• 3: diffuse 
•  
PICASSO VASCULAR ARCHITECTURE  
• Vessels without dilatation 
– A :Roundish following crypt architecture 
– B: Vessels not visible (scar) 
– C:Sparse (deep) vessels without dilatation 
• I  Vessels  with dilatation  
– A roundish with dilatation 
– B crowded or tortuous superficial vessels with 
dilatation 
• II Intramucosal bleeding  
– A roundish with dilatation 
– B crowded or tortuous superficial vessels with 
dilatation 
• III - Luminal bleeding  
• A roundish with dilatation 
• B crowded or tortuous superficial vessels with 
dilatation 
 
